---
title: "Galectin Therapeutics Awards Retention Bonuses to Chief Medical and Financial Officers"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/273285494.md"
datetime: "2026-01-21T22:01:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273285494.md)
  - [en](https://longbridge.com/en/news/273285494.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273285494.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/273285494.md) | [繁體中文](https://longbridge.com/zh-HK/news/273285494.md)


# Galectin Therapeutics Awards Retention Bonuses to Chief Medical and Financial Officers

Galectin Therapeutics Inc. has approved cash retention bonuses for two of its top executives. Chief Medical Officer Dr. Khurram Jamil will receive a $300,000 bonus, while Chief Financial Officer Jack Callicutt will receive $150,000. Each bonus will be paid in three equal installments on June 1, September 1, and December 1, 2026. The bonuses must be repaid if the officers resign without good reason or are terminated for cause before December 31, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-001866), on January 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### 相关股票

- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [Direxion S&P Biotech Bear 3X (LABD.US)](https://longbridge.com/zh-CN/quote/LABD.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-CN/quote/IBBQ.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md)
- [Galectin Therap (GALT.US)](https://longbridge.com/zh-CN/quote/GALT.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md)

## 相关资讯与研究

- [Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study | INTS Stock News](https://longbridge.com/zh-CN/news/278874097.md)
- [BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering | BTAI Stock News](https://longbridge.com/zh-CN/news/278602207.md)
- [Calidi Biotherapeutics Raises $6.03 Million in Unit Offering; Adds Warrant Agent and Amends Legacy Warrants](https://longbridge.com/zh-CN/news/278783738.md)
- [Galecto Rebrands as Damora Therapeutics with New Ticker](https://longbridge.com/zh-CN/news/278556054.md)
- [Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium | IMUX Stock News](https://longbridge.com/zh-CN/news/278536359.md)